Login
Companies $GRAL
$108.50 +$2.90 (2.75%) After hours
GRAIL, Inc. logo

GRAIL, Inc.

grail.com

What Do They Do?

Sells Galleri, a blood test that screens for many cancers, to patients and healthcare customers.

How Do They Make Money?

Screening is the main business: patients and healthcare customers pay for tests, with invoices generally due within 30 days. Biopharmaceutical partners pay for pilot studies as work is completed and for longer development projects as services progress.

revenue
SegmentShareRevenue
Screening revenue
Sold outright

94%
FY2022: 72%
Development Services
Recurring
5.8%
FY2022: 28%

Who Are Their Customers?

Patients obtain tests through healthcare, employer and insurance partners, or directly via telemedicine; biopharmaceutical companies engage GRAIL for development studies.

Do Revenues Turn Into Profits?

No. It lost $408.4M in FY2025.

Operating income, FY2025
−382% of revenue
▲ +74% (Loss) vs FY2024 (−$2.2B, −1743%)
Net income, FY2025
−277% of revenue
▲ +80% (Loss) vs FY2024 (−$2B, −1614%)
Free cash flow, FY2025
−204% of revenue
▲ +49% (Loss) vs FY2024 (−$582.4M, −464%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +4%
vs $36.2M in Q3 FY2025
Net income
▼ −16% (Loss)
vs −$89M in Q3 FY2025
Screening revenue share of revenue vs 90.6% in Q3 FY2025
  • Jun 1, 2026 Josh Ofman became chief executive officer
Revenue over time
Screening revenue Development Services
$200M$100M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support